Cargando…

Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada

BACKGROUND: When the novel coronavirus pandemic emerged in March 2020, many settings across Canada and the USA were already contending with an existing crisis of drug overdoses due to the toxic unregulated drug supply. In response, the Canadian province of British Columbia (BC) released innovative r...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshkforoush, Mana, DeBeck, Kora, Brar, Rupinder, Fairbairn, Nadia, Cui, Zishan, Milloy, M.-J., Buxton, Jane, Oldenburger, Tanis, McLellan, Will, Kendall, Perry, Sedgemore, Kali, Wilson, Dean, Kerr, Thomas, Hayashi, Kanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131310/
https://www.ncbi.nlm.nih.gov/pubmed/35614440
http://dx.doi.org/10.1186/s12954-022-00632-6
_version_ 1784713156965171200
author Moshkforoush, Mana
DeBeck, Kora
Brar, Rupinder
Fairbairn, Nadia
Cui, Zishan
Milloy, M.-J.
Buxton, Jane
Oldenburger, Tanis
McLellan, Will
Kendall, Perry
Sedgemore, Kali
Wilson, Dean
Kerr, Thomas
Hayashi, Kanna
author_facet Moshkforoush, Mana
DeBeck, Kora
Brar, Rupinder
Fairbairn, Nadia
Cui, Zishan
Milloy, M.-J.
Buxton, Jane
Oldenburger, Tanis
McLellan, Will
Kendall, Perry
Sedgemore, Kali
Wilson, Dean
Kerr, Thomas
Hayashi, Kanna
author_sort Moshkforoush, Mana
collection PubMed
description BACKGROUND: When the novel coronavirus pandemic emerged in March 2020, many settings across Canada and the USA were already contending with an existing crisis of drug overdoses due to the toxic unregulated drug supply. In response, the Canadian province of British Columbia (BC) released innovative risk mitigation prescribing (RMP) guidelines for medical professionals to prescribe pharmaceutical alternatives to unregulated drugs in an effort to support the self-isolation of people who use unregulated drugs (PWUD) in preventing both SARS-CoV-2 virus infection and overdoses. We sought to assess the level of awareness of RMP and identify factors associated with this awareness among PWUD in Vancouver, BC. METHODS: Cross-sectional data were derived from participants enrolled in three community-recruited prospective cohort studies of PWUD in Vancouver, interviewed between July and November 2020. Multivariable logistic regression analysis was used to identify factors associated with awareness of RMP. RESULTS: Among 633 participants, 302 (47.7%) had heard of RMP. Of those 302 participants, 199 (65.9%) had never tried to access RMP services, ten (3.3%) made an unsuccessful attempt to access RMP, and 93 (30.8%) received RMP. In the multivariable analysis, participants who had awareness of RMP guidelines were more likely to self-identify as white (adjusted odds ratio [AOR] = 1.47; 95% confidence interval [CI]: 1.01, 2.13), to have completed secondary school education or higher (AOR = 1.67; 95% CI: 1.16, 2.39), to have used drugs at a supervised consumption or overdose prevention site in the past six months (AOR = 1.66; 95% CI: 1.10, 2.52), and to have received opioid agonist therapy as treatment for opioid use disorder in the past six months (AOR = 1.51; 95% CI: 1.02, 2.24). CONCLUSION: At least four months after the release of the guidelines, RMP was known to less than half of our study participants, warranting urgent educational efforts for PWUD, particularly among racialized groups and those who were not accessing other harm reduction services. Furthermore, the majority of participants who were aware of RMP guidelines had never tried to access the service, suggesting the need to improve perceived accessibility and knowledge of eligibility criteria.
format Online
Article
Text
id pubmed-9131310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91313102022-05-25 Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada Moshkforoush, Mana DeBeck, Kora Brar, Rupinder Fairbairn, Nadia Cui, Zishan Milloy, M.-J. Buxton, Jane Oldenburger, Tanis McLellan, Will Kendall, Perry Sedgemore, Kali Wilson, Dean Kerr, Thomas Hayashi, Kanna Harm Reduct J Research BACKGROUND: When the novel coronavirus pandemic emerged in March 2020, many settings across Canada and the USA were already contending with an existing crisis of drug overdoses due to the toxic unregulated drug supply. In response, the Canadian province of British Columbia (BC) released innovative risk mitigation prescribing (RMP) guidelines for medical professionals to prescribe pharmaceutical alternatives to unregulated drugs in an effort to support the self-isolation of people who use unregulated drugs (PWUD) in preventing both SARS-CoV-2 virus infection and overdoses. We sought to assess the level of awareness of RMP and identify factors associated with this awareness among PWUD in Vancouver, BC. METHODS: Cross-sectional data were derived from participants enrolled in three community-recruited prospective cohort studies of PWUD in Vancouver, interviewed between July and November 2020. Multivariable logistic regression analysis was used to identify factors associated with awareness of RMP. RESULTS: Among 633 participants, 302 (47.7%) had heard of RMP. Of those 302 participants, 199 (65.9%) had never tried to access RMP services, ten (3.3%) made an unsuccessful attempt to access RMP, and 93 (30.8%) received RMP. In the multivariable analysis, participants who had awareness of RMP guidelines were more likely to self-identify as white (adjusted odds ratio [AOR] = 1.47; 95% confidence interval [CI]: 1.01, 2.13), to have completed secondary school education or higher (AOR = 1.67; 95% CI: 1.16, 2.39), to have used drugs at a supervised consumption or overdose prevention site in the past six months (AOR = 1.66; 95% CI: 1.10, 2.52), and to have received opioid agonist therapy as treatment for opioid use disorder in the past six months (AOR = 1.51; 95% CI: 1.02, 2.24). CONCLUSION: At least four months after the release of the guidelines, RMP was known to less than half of our study participants, warranting urgent educational efforts for PWUD, particularly among racialized groups and those who were not accessing other harm reduction services. Furthermore, the majority of participants who were aware of RMP guidelines had never tried to access the service, suggesting the need to improve perceived accessibility and knowledge of eligibility criteria. BioMed Central 2022-05-25 /pmc/articles/PMC9131310/ /pubmed/35614440 http://dx.doi.org/10.1186/s12954-022-00632-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Moshkforoush, Mana
DeBeck, Kora
Brar, Rupinder
Fairbairn, Nadia
Cui, Zishan
Milloy, M.-J.
Buxton, Jane
Oldenburger, Tanis
McLellan, Will
Kendall, Perry
Sedgemore, Kali
Wilson, Dean
Kerr, Thomas
Hayashi, Kanna
Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title_full Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title_fullStr Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title_full_unstemmed Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title_short Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada
title_sort low awareness of risk mitigation prescribing in response to dual crises of covid-19 and overdose deaths among people who use unregulated drugs in vancouver, canada
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131310/
https://www.ncbi.nlm.nih.gov/pubmed/35614440
http://dx.doi.org/10.1186/s12954-022-00632-6
work_keys_str_mv AT moshkforoushmana lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT debeckkora lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT brarrupinder lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT fairbairnnadia lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT cuizishan lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT milloymj lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT buxtonjane lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT oldenburgertanis lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT mclellanwill lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT kendallperry lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT sedgemorekali lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT wilsondean lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT kerrthomas lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada
AT hayashikanna lowawarenessofriskmitigationprescribinginresponsetodualcrisesofcovid19andoverdosedeathsamongpeoplewhouseunregulateddrugsinvancouvercanada